105 related articles for article (PubMed ID: 22844128)
21. Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
Tanaka K; Kawamoto H; Saito I; Yoshimura K; Fukuda H; Iwamoto Y
Jpn J Clin Oncol; 2009 Apr; 39(4):271-3. PubMed ID: 19155282
[TBL] [Abstract][Full Text] [Related]
22. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
23. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
24. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
25. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
26. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
27. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
Moore KN; Tian C; McMeekin DS; Thigpen JT; Randall ME; Gallion HH
Cancer; 2010 Dec; 116(23):5407-14. PubMed ID: 20737572
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
[TBL] [Abstract][Full Text] [Related]
29. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
30. Tumor burden modeling versus progression-free survival for phase II decision making.
Kaiser LD
Clin Cancer Res; 2013 Jan; 19(2):314-9. PubMed ID: 23172885
[TBL] [Abstract][Full Text] [Related]
31. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
32. Assessing temporal agreement between central and local progression-free survival times.
Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
[TBL] [Abstract][Full Text] [Related]
33. Missing data and censoring in the analysis of progression-free survival in oncology clinical trials.
Denne JS; Stone AM; Bailey-Iacona R; Chen TT
J Biopharm Stat; 2013; 23(5):951-70. PubMed ID: 23957509
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for the assessment of progression in randomised cancer treatment trials.
Dancey JE; Dodd LE; Ford R; Kaplan R; Mooney M; Rubinstein L; Schwartz LH; Shankar L; Therasse P
Eur J Cancer; 2009 Jan; 45(2):281-9. PubMed ID: 19097775
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of treatment effect due to measurement variability in assessment of progression-free survival.
Hong S; Schmitt N; Stone A; Denne J
Pharm Stat; 2012; 11(5):394-402. PubMed ID: 22740352
[TBL] [Abstract][Full Text] [Related]
36. The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).
Niimi M; Yamamoto S; Fukuda H; Ishizuka N; Akaza H
Jpn J Clin Oncol; 2002 Jan; 32(1):19-26. PubMed ID: 11932358
[TBL] [Abstract][Full Text] [Related]
37. Proposal for the use of progression-free survival in unblinded randomized trials.
Freidlin B; Korn EL; Hunsberger S; Gray R; Saxman S; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2122-6. PubMed ID: 17513819
[TBL] [Abstract][Full Text] [Related]
38. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
Hsu EJ; Lin TA; Dabush DR; McCaw Z; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Noticewala S; Yang Y; Sherry AD; Fuller CD; Thomas CR; Tang C; Msaouel P; Das P; Huang B; Tian L; Sun R; Lee JJ; Meirson T; Ludmir EB
J Natl Cancer Inst; 2024 Jun; 116(6):990-994. PubMed ID: 38331394
[TBL] [Abstract][Full Text] [Related]
39. Design of cancer trials based on progression-free survival with intermittent assessment.
Zeng L; Cook RJ; Lee KA
Stat Med; 2018 May; 37(12):1947-1959. PubMed ID: 29582452
[TBL] [Abstract][Full Text] [Related]
40. Model free audit methodology for bias evaluation of tumour progression in oncology.
Stone A; Macpherson E; Smith A; Jennison C
Pharm Stat; 2015; 14(6):455-63. PubMed ID: 26435269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
